参考文献[1]
中华医学会心血管病学分会介入心脏病学组,中华心血管病杂志编辑委员会. 中国经皮冠状动脉介入治疗指南2012(简本)[J]. 中华心血管病杂志,2012,40(4):271-277. .
[2]
中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 经皮冠状动脉介入治疗指南(2009)[J].中华心血管病杂志,2009,37(1):4-25. .
[3]
RoffiM, PatronoC, ColletJP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-segment Elevation of the European Society of Cardiology (ESC)[J].Eur Heart J, 2016, 37(3):267-315..
[4]
LevineGN, BatesER, BlankenshipJC, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J]. Circulation, 2016, 133:1135-1147. .
[5]
MontalescotG, SechtemU, AchenbachS, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology[J]. Eur Heart J, 2013,34(38):2949-3003. .
[6]
O′GaraPT, KushnerFG, AscheimDD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2013,127(4):e362-e425. .
[7]
WindeckerS, KolhP, AlfonsoF, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)[J]. Eur Heart J, 2014,35(37):2541-2619. .
[8]
FihnSD, BlankenshipJC, AlexanderKP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons[J].J Thorac Cardiovasc Surg, 2015, 149(3):e5-e23..
[9]
AmsterdamEA, WengerNK, BrindisRG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2014,130(25):e344-e426. .
[10]
NashefSA, RoquesF, SharplesLD, et al. EuroSCORE Ⅱ[J]. Eur J Cardiothorac Surg,2012,41(4):734-745..
[11]
SianosG, MorelMA, KappeteinAP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease[J]. EuroIntervention, 2005,1(2):219-227.
[12]
FarooqV, van KlaverenD, SteyerbergEW, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score Ⅱ[J]. Lancet, 2013,381(9867):639-650. .
[13]
XuB, GénéreuxP, YangY, et al. Validation and comparison of the long-term prognostic capability of the SYNTAX score-Ⅱ among 1528 consecutive patients who underwent left main percutaneous coronary intervention[J]. JACC Cardiovasc Interv, 2014,7(10):1128-1137. .
[14]
ChenSL, HanYL, ZhangYJ, et al. The anatomic- and clinical-based NERS (new risk stratification) score Ⅱ to predict clinical outcomes after stenting unprotected left main coronary artery disease: results from a multicenter, prospective, registry study[J]. JACC Cardiovasc Interv, 2013,6(12):1233-1241. .
[15]
BittlJA, HeY, JacobsAK, et al. Bayesian methods affirm the use of percutaneous coronary intervention to improve survival in patients with unprotected left main coronary artery disease[J]. Circulation, 2013,127(22):2177-2185. .
[16]
HuebW, LopesN, GershBJ, et al. Ten-year follow-up survival of the medicine, angioplasty, or surgery study (MASS Ⅱ): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease[J]. Circulation, 2010,122(10):949-957. .
[17]
SmithPK, CaliffRM, TuttleRH, et al. Selection of surgical or percutaneous coronary intervention provides differential longevity benefit[J]. Ann Thorac Surg, 2006,82(4):1420-1428; . .
[18]
FryeRL, AugustP, BrooksMM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease[J]. N Engl J Med, 2009,360(24):2503-2515. .
[19]
ChaitmanBR, HardisonRM, AdlerD, et al. The bypass angioplasty revascularization investigation 2 diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction[J]. Circulation, 2009,120(25):2529-2540. .
[20]
HannanEL, SamadashviliZ, CozzensK, et al. Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York[J]. Circulation, 2012,125(15):1870-1879. .
[21]
HannanEL, WuC, WalfordG, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease[J]. N Engl J Med, 2008,358(4):331-341. .
[22]
De BruyneB, PijlsNH, KalesanB, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease[J]. N Engl J Med, 2012,367(11):991-1001. .
[23]
BodenWE, O′RourkeRA, TeoKK, et al. Optimal medical therapy with or without PCI for stable coronary disease[J]. N Engl J Med, 2007,356(15):1503-1516. .
[24]
ShawLJ, BermanDS, MaronDJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy[J]. Circulation, 2008,117(10):1283-1291. .
[25]
BangaloreS, PursnaniS, KumarS, et al. Percutaneous coronary intervention versus optimal medical therapy for prevention of spontaneous myocardial infarction in subjects with stable ischemic heart disease[J]. Circulation, 2013,127(7):769-781. .
[26]
PursnaniS, KorleyF, GopaulR, et al. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials[J]. Circ Cardiovasc Interv, 2012,5(4):476-490. .
[27]
SchömigA, MehilliJ, de WahaA, et al. A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease[J]. J Am Coll Cardiol, 2008,52(11):894-904. .
[28]
ThomasS, GokhaleR, BodenWE, et al. A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris[J]. Can J Cardiol, 2013,29(4):472-482. .
[29]
AzizO, RaoC, PanesarSS, et al. Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery[J]. BMJ, 2007,334(7594):617. .
[30]
BlazekS, HolzheyD, JungertC, et al. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 10-year follow-up of a randomized trial[J]. JACC Cardiovasc Interv, 2013,6(1):20-26. .
[31]
MohrFW, MoriceMC, KappeteinAP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial[J]. Lancet, 2013,381(9867):629-638. .
[32]
HeadSJ, DavierwalaPM, SerruysPW, et al. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial[J]. Eur Heart J, 2014,35(40):2821-2830. .
[33]
FarkouhME, DomanskiM, SleeperLA, et al. Strategies for multivessel revascularization in patients with diabetes[J]. N Engl J Med, 2012,367(25):2375-2384. .
[34]
SciricaBM, MorrowDA, BudajA, et al. Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36) trial[J]. J Am Coll Cardiol, 2009,53(16):1411-1421. .
[35]
AkkerhuisKM, KlootwijkPA, LindeboomW, et al. Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients[J]. Eur Heart J, 2001,22(21):1997-2006. .
[36]
KatritsisDG, SiontisGC, KastratiA, et al. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes[J]. Eur Heart J, 2011,32(1):32-40. .
[37]
MehtaSR, GrangerCB, BodenWE, et al. Early versus delayed invasive intervention in acute coronary syndromes[J]. N Engl J Med, 2009,360(21):2165-2175. .
[38]
BavryAA, KumbhaniDJ, RassiAN, et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials[J]. J Am Coll Cardiol, 2006,48(7):1319-1325. .
[39]
FoxKA, ClaytonTC, DammanP, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data[J]. J Am Coll Cardiol, 2010,55(22):2435-2445. .
[40]
AmsterdamEA, KirkJD, DiercksDB, et al. Immediate exercise testing to evaluate low-risk patients presenting to the emergency department with chest pain[J]. J Am Coll Cardiol, 2002,40(2):251-256.
[41]
ZhangQ, ZhangRY, QiuJP, et al. One-year clinical outcome of interventionalist-versus patient-transfer strategies for primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results from the REVERSE-STEMI study[J]. Circ Cardiovasc Qual Outcomes, 2011,4(3):355-362. .
[42]
McNamaraRL, HerrinJ, WangY, et al. Impact of delay in door-to-needle time on mortality in patients with ST-segment elevation myocardial infarction[J]. Am J Cardiol, 2007,100(8):1227-1232. .
[43]
BorgiaF, GoodmanSG, HalvorsenS, et al. Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis[J]. Eur Heart J, 2010,31(17):2156-2169. .
[44]
DanchinN, CosteP, FerrièresJ, et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardial infarction (FAST-MI)[J]. Circulation, 2008,118(3):268-276. .
[45]
BhattNS, SolhpourA, BalanP, et al. Comparison of in-hospital outcomes with low-dose fibrinolytic therapy followed by urgent percutaneous coronary intervention versus percutaneous coronary intervention alone for treatment of ST-elevation myocardial infarction[J]. Am J Cardiol, 2013,111(11):1576-1579. .
[46]
ArmstrongPW, GershlickAH, GoldsteinP, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction[J]. N Engl J Med, 2013,368(15):1379-1387. .
[47]
ShenLH, WanF, ShenL, et al. Pharmacoinvasive therapy for ST elevation myocardial infarction in China: a pilot study[J]. J Thromb Thrombolysis, 2012,33(1):101-108. .
[48]
HanYL, LiuJN, JingQM, et al. The efficacy and safety of pharmacoinvasive therapy with prourokinase for acute ST-segment elevation myocardial infarction patients with expected long percutaneous coronary intervention-related delay[J]. Cardiovasc Ther, 2013,31(5):285-290. .
[49]
WaldDS, MorrisJK, WaldNJ, et al. Randomized trial of preventive angioplasty in myocardial infarction[J]. N Engl J Med, 2013,369(12):1115-1123. .
[50]
GershlickAH, KhanJN, KellyDJ, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial[J]. J Am Coll Cardiol, 2015,65(10):963-972. .
[51]
EngstrømT, KelbækH, HelqvistS, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial[J].Lancet,2015,386(9994):665-671.
[53]
SarathyK, NagarajaV, KapurA, et al. Target-vessel versus multivessel revascularisation in ST-elevation myocardial infarction: a meta-analysis of randomised trials[J]. Heart Lung Circ, 2015,24(4):327-334. .
[54]
KornowskiR, MehranR, DangasG, et al. Prognostic impact of staged versus " one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial[J]. J Am Coll Cardiol, 2011,58(7):704-711. .
[55]
ManariA, VaraniE, GuastarobaP, et al. Long-term outcome in patients with ST segment elevation myocardial infarction and multivessel disease treated with culprit-only, immediate, or staged multivessel percutaneous revascularization strategies: Insights from the REAL registry[J]. Catheter Cardiovasc Interv, 2014,84(6):912-922. .
[56]
VlaarPJ, MahmoudKD, HolmesDR, et al. Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis[J]. J Am Coll Cardiol, 2011,58(7):692-703. .
[57]
中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南[J]. 中华心血管病杂志,2015,43(5):380-393..
[58]
CantorWJ, FitchettD, BorgundvaagB, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction[J]. N Engl J Med, 2009,360(26):2705-2718. .
[59]
BøhmerE, HoffmannP, AbdelnoorM, et al. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (Norwegian study on district treatment of ST-elevation myocardial infarction)[J]. J Am Coll Cardiol, 2010,55(2):102-110. .
[60]
DiMC, DudekD, PiscioneF, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the combined abciximab reteplase stent study in acute myocardial infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial[J]. Lancet, 2008,371(9612):559-568. .
[61]
HochmanJS, SleeperLA, WhiteHD, et al. One-year survival following early revascularization for cardiogenic shock[J]. JAMA, 2001,285(2):190-192.
[62]
GershlickAH, Stephens-LloydA, HughesS, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction[J]. N Engl J Med, 2005,353(26):2758-2768. .
[63]
ValgimigliM, GagnorA, CalabróP, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial[J]. Lancet, 2015,385(9986):2465-2476. .
[64]
GengW, FuX, GuX, et al. Safety and feasibility of transulnar versus transradial artery approach for coronary catheterization in non-selective patients[J]. Chin Med J (Engl), 2014,127(7):1222-1228.
[65]
PariseH, MaeharaA, StoneGW, et al. Meta-analysis of randomized studies comparing intravascular ultrasound versus angiographic guidance of percutaneous coronary intervention in pre-drug-eluting stent era[J]. Am J Cardiol, 2011,107(3):374-382. .
[66]
WitzenbichlerB, MaeharaA, WeiszG, et al. Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study[J]. Circulation, 2014,129(4):463-470. .
[67]
ParkSJ, KimYH, ParkDW, et al. Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis[J].Circ Cardiovasc Interv, 2009, 2(3):167-177..
[68]
ParkY, ParkHS, JangGL, et al. Intravascular ultrasound guided recanalization of stumpless chronic total occlusion[J]. Int J Cardiol, 2011,148(2):174-178. .
[69]
PijlsNH, van SchaardenburghP, ManoharanG, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study[J]. J Am Coll Cardiol, 2007,49(21):2105-2111. .
[70]
ToninoPA, De BruyneB, PijlsNH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention[J]. N Engl J Med, 2009,360(3):213-224. .
[71]
LiJ, ElrashidiMY, FlammerAJ, et al. Long-term outcomes of fractional flow reserve-guided vs. angiography-guided percutaneous coronary intervention in contemporary practice[J]. Eur Heart J, 2013,34(18):1375-1383. .
[72]
ChenSL, YeF, ZhangJJ, et al. Randomized comparison of FFR-guided and angiography-guided provisional stenting of true coronary bifurcation lesions: the DKCRUSH-Ⅵ trial (double kissing crush versus provisional stenting technique for treatment of coronary bifurcation lesions Ⅵ)[J]. JACC Cardiovasc Interv, 2015,8(4):536-546. .
[73]
HanY, XuB, JingQ, et al. A randomized comparison of novel biodegradable polymer- and durable polymer-coated cobalt-chromium sirolimus-eluting stents[J]. JACC Cardiovasc Interv, 2014,7(12):1352-1360. .
[74]
HanY, XuB, XuK, et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial[J]. Circ Cardiovasc Interv, 2016,9(2):e003145. .
[75]
BangaloreS, KumarS, FusaroM, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117762 patient-years of follow-up from randomized trials[J]. Circulation, 2012,125(23):2873-2891. .
[76]
StefaniniGG, BaberU, WindeckerS, et al. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials[J]. Lancet, 2013,382(9908):1879-1888. .
[77]
RäberL, KelbækH, OstojicM, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial[J]. JAMA, 2012,308(8):777-787. .
[78]
SabateM, CequierA, IñiguezA, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial[J]. Lancet, 2012,380(9852):1482-1490. .
[79]
BangaloreS, KumarS, FusaroM, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22844 patient years of follow-up from randomised trials[J]. BMJ, 2012,345:e5170.
[80]
StettlerC, AllemannS, WandelS, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis[J]. BMJ, 2008,337:a1331.
[81]
TsaiTT, MessengerJC, BrennanJM, et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database[J]. J Am Coll Cardiol, 2011,58(18):1859-1869. .
[82]
ShenoyC, BouraJ, OrshawP, et al. Drug-eluting stents in patients with chronic kidney disease: a prospective registry study[J]. PLoS One, 2010,5(11):e15070. .
[83]
Al-LameeR, IelasiA, LatibA, et al. Comparison of long-term clinical and angiographic outcomes following implantation of bare metal stents and drug-eluting stents in aorto-ostial lesions[J]. Am J Cardiol, 2011,108(8):1055-1060. .
[84]
LeeSW, KimSH, KimSO, et al. Comparative long-term efficacy and safety of drug-eluting stent versus coronary artery bypass grafting in ostial left main coronary artery disease: analysis of the MAIN-COMPARE registry[J]. Catheter Cardiovasc Interv, 2012,80(2):206-212. .
[85]
MehilliJ, PacheJ, Abdel-WahabM, et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial[J]. Lancet, 2011,378(9796):1071-1078. .
[86]
FröbertO, SchersténF, JamesSK, et al. Long-term safety and efficacy of drug-eluting and bare metal stents in saphenous vein grafts[J]. Am Heart J, 2012,164(1):87-93. .
[87]
KastratiA, MehilliJ, von BeckerathN, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial[J].JAMA, 2005, 293(2):165-171..
[88]
MehilliJ, ByrneRA, TirochK, et al. Randomized trial of paclitaxel-versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (intracoronary stenting and angiographic results: drug eluting stents for in-stent restenosis 2) study[J]. J Am Coll Cardiol, 2010,55(24):2710-2716. .
[89]
CrudenNL, HardingSA, FlapanAD, et al. Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery[J]. Circ Cardiovasc Interv, 2010,3(3):236-242. .
[90]
GrinesCL, BonowRO, CaseyDE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians[J]. J Am Coll Cardiol, 2007,49(6):734-739. .
[91]
GaoR, YangY, HanY, et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China Trial[J]. J Am Coll Cardiol, 2015,66(21):2298-2309. .
[92]
ByrneRA, NeumannFJ, MehilliJ, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial[J]. Lancet, 2013,381(9865):461-467. .
[93]
XuB, GaoR, WangJ, et al. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial[J]. JACC Cardiovasc Interv, 2014,7(2):204-211. .
[94]
StoneGW, MaeharaA, WitzenbichlerB, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial[J]. JAMA, 2012,307(17):1817-1826. .
[95]
FröbertO, LagerqvistB, OlivecronaGK, et al. Thrombus aspiration during ST-segment elevation myocardial infarction[J]. N Engl J Med, 2013,369(17):1587-1597. .
[96]
JollySS, CairnsJA, YusufS, et al. Stroke in the TOTAL trial: a randomized trial of routine thrombectomy vs. percutaneous coronary intervention alone in ST elevation myocardial infarction[J]. Eur Heart J, 2015,36(35):2364-2372. .
[97]
VaquerizoB, SerraA, MirandaF, et al. Aggressive plaque modification with rotational atherectomy and/or cutting balloon before drug-eluting stent implantation for the treatment of calcified coronary lesions[J]. J Interv Cardiol, 2010,23(3):240-248. .
[98]
Abdel-WahabM, RichardtG, JoachimBH, et al. High-speed rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: the randomized ROTAXUS (rotational atherectomy prior to taxus stent treatment for complex native coronary artery disease) trial[J]. JACC Cardiovasc Interv, 2013,6(1):10-19. .
[99]
BittlJA, ChewDP, TopolEJ, et al. Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty[J]. J Am Coll Cardiol, 2004,43(6):936-942. .
[100]
BuerkeM, ProndzinskyR, LemmH, et al. Intra-aortic balloon counterpulsation in the treatment of infarction-related cardiogenic shock--review of the current evidence[J]. Artif Organs, 2012,36(6):505-511. .
[101]
SjauwKD, EngströmAE, VisMM, et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines[J].Eur Heart J, 2009, 30(4):459-468..
[102]
BahekarA, SinghM, SinghS, et al. Cardiovascular outcomes using intra-aortic balloon pump in high-risk acute myocardial infarction with or without cardiogenic shock: a meta-analysis[J]. J Cardiovasc Pharmacol Ther, 2012,17(1):44-56. .
[103]
杨新春,张大鹏,王乐丰,等. 冠状动脉内应用国产替罗非班对急性ST段抬高心肌梗死急诊介入治疗后心肌灌注和临床预后的影响[J].中华心血管病杂志,2007,35(6):517-522. .
[104]
ZhuTQ, ZhangQ, QiuJP, et al. Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the ICT-AMI study[J]. Int J Cardiol, 2013,165(3):437-443. .
[105]
NiccoliG, BurzottaF, GaliutoL, et al. Myocardial no-reflow in humans[J]. J Am Coll Cardiol, 2009,54(4):281-292. .
[106]
ZhouSS, TianF, ChenYD, et al. Combination therapy reduces the incidence of no-reflow after primary per-cutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction[J]. J Geriatr Cardiol, 2015,12(2):135-142. .
[107]
孙宇珺,周雯,丁嵩,等. 经靶向灌注导管在冠状动脉靶病变远段给予替罗非班对急性冠状动脉综合征患者心肌灌注的影响[J].中国介入心脏病学杂志,2015,23(1):5-10. .
[108]
IakovouI, SchmidtT, BonizzoniE, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents[J]. JAMA, 2005,293(17):2126-2130. .
[109]
DaemenJ, WenaweserP, TsuchidaK, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study[J]. Lancet, 2007,369(9562):667-678. .
[110]
ManoukianSV, FeitF, MehranR, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial[J]. J Am Coll Cardiol, 2007,49(12):1362-1368. .
[111]
LiC, HirshJ, XieC, et al. Reversal of the anti-platelet effects of aspirin and clopidogrel[J]. J Thromb Haemost, 2012,10(4):521-528. .
[112]
MakrisM, Van VeenJJ, TaitCR, et al. Guideline on the management of bleeding in patients on antithrombotic agents[J]. Br J Haematol, 2013,160(1):35-46. .
[113]
AhmedB, PiperWD, MalenkaD, et al. Significantly improved vascular complications among women undergoing percutaneous coronary intervention: a report from the northern New England percutaneous coronary intervention registry[J]. Circ Cardiovasc Interv, 2009,2(5):423-429. .
[114]
ApplegateRJ, SacrintyMT, KutcherMA, et al. Trends in vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention via the femoral artery, 1998 to 2007[J].JACC Cardiovasc Interv, 2008, 1(3):317-326..
[115]
FreestoneB, NolanJ. Transradial cardiac procedures: the state of the art[J]. Heart, 2010,96(11):883-891. .
[116]
LiJ, LiY, WangX, et al. Age, estimated glomerular filtration rate and ejection fraction score predicts contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease: insight from the TRACK-D study[J]. Chin Med J (Engl), 2014,127(12):2332-2336.
[117]
QianG, FuZ, GuoJ, et al. Prevention of contrast-induced nephropathy by central benous pressure-guided fluid administration in chronic kidney disease and congestive heart failure patients[J]. JACC Cardiovasc Interv, 2016,9(1):89-96. .
[118]
LiY, LiuY, FuL, et al. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials[J]. PLoS One, 2012,7(4):e34450. .
[119]
LeonciniM, TosoA, MaioliM, et al. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome:results from the PRATO-ACS study (protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome)[J]. J Am Coll Cardiol, 2014,63(1):71-79. .
[120]
HanY, ZhuG, HanL, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease[J]. J Am Coll Cardiol, 2014,63(1):62-70. .
[121]
MertenGJ, BurgessWP, GrayLV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial[J]. JAMA, 2004,291(19):2328-2334. .
[122]
BrarSS, ShenAY, JorgensenMB, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial[J]. JAMA, 2008,300(9):1038-1046. .
[123]
AspelinP, AubryP, FranssonSG, et al. Nephrotoxic effects in high-risk patients undergoing angiography[J]. N Engl J Med, 2003,348(6):491-499. .
[124]
SolomonRJ, NatarajanMK, DoucetS, et al. Cardiac angiography in renally impaired patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease[J]. Circulation, 2007,115(25):3189-3196. .
[125]
JoSH, YounTJ, KooBK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial[J]. J Am Coll Cardiol, 2006,48(5):924-930. .
[126]
MarenziG, AssanelliE, CampodonicoJ, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality[J]. Ann Intern Med, 2009,150(3):170-177.
[127]
MarenziG, FerrariC, MaranaI, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (induced diuresis with matched hydration compared to standard hydration for contrast induced nephropathy prevention) trial[J]. JACC Cardiovasc Interv, 2012,5(1):90-97. .
[128]
BriguoriC, ViscontiG, FocaccioA, et al. Renal insufficiency after contrast media administration trial Ⅱ(REMEDIAL Ⅱ): renalguard system in high-risk patients for contrast-induced acute kidney injury[J]. Circulation, 2011,124(11):1260-1269. .
[129]
MarenziG, MaranaI, LauriG, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration[J]. N Engl J Med, 2003,349(14):1333-1340. .
[130]
CruzDN, GohCY, MarenziG, et al. Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review[J]. Am J Med, 2012,125(1):66-78.e3. .
[131]
GurbelPA, BlidenKP, ButlerK, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study[J]. Circulation, 2009,120(25):2577-2585. .
[132]
ChenY, DongW, WanZ, et al. Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome: A pharmacodynamic analysis[J]. Int J Cardiol, 2015,201:545-546. .
[133]
LiH, ButlerK, YangL, et al. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study[J]. Clin Drug Investig, 2012,32(2):87-97. .
[134]
王贺阳,苏晞,沈成兴,等. 替格瑞洛在急性冠脉综合征患者中应用的安全性和有效性分析[J].中国循证心血管医学杂志,2015,(4):468-471. .
[135]
WallentinL, JamesS, StoreyRF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial[J]. Lancet, 2010,376(9749):1320-1328. .
[136]
LiangZY, HanYL, ZhangXL, et al. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation[J]. EuroIntervention, 2013,9(3):316-327. .
[137]
LiP, YangY, ChenT, et al. Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial[J]. Sci Rep, 2015,5:13789. .
[138]
StoreyRF, BeckerRC, HarringtonRA, et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes[J]. Eur Heart J, 2011,32(23):2945-2953. .
[139]
GaubertM, LaineM, RichardT, et al. Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients[J]. Int J Cardiol, 2014,173(1):120-121. .
[140]
DiSG, PattiG, PasceriV, et al. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized trial[J]. J Am Coll Cardiol, 2010,56(7):550-557. .
[141]
WidimskyP, MotovskáZ, SimekS, et al. Clopidogrel pre-treatment in stable angina: for all patients>6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? a randomized multicentre trial PRAGUE-8[J]. Eur Heart J, 2008,29(12):1495-1503. .
[142]
BaigentC, BlackwellL, CollinsR, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials[J]. Lancet, 2009,373(9678):1849-1860. .
[143]
SteinhublSR, BergerPB, MannJT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial[J]. JAMA, 2002,288(19):2411-2420.
[144]
ValgimigliM, CampoG, MontiM, et al. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial[J]. Circulation, 2012,125(16):2015-2026. .
[145]
GwonHC, HahnJY, ParkKW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of Xience/Promus bersus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study[J]. Circulation, 2012,125(3):505-513. .
[146]
HanY, JingQ, LiY, et al. Sustained clinical safety and efficacy of a biodegradable-polymer coated sirolimus-eluting stent in "real-world" practice: three-year outcomes of the CREATE (multi-center registry of EXCEL biodegradable polymer drug eluting stents) study[J]. Catheter Cardiovasc Interv, 2012,79(2):211-216. .
[147]
FeresF, CostaRA, AbizaidA, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial[J]. JAMA, 2013,310(23):2510-2522. .
[148]
KimBK, HongMK, ShinDH, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (real safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation)[J]. J Am Coll Cardiol, 2012,60(15):1340-1348. .
[149]
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients[J]. BMJ, 2002,324(7329):71-86.
[150]
PatronoC, AndreottiF, ArnesenH, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis[J]. Eur Heart J, 2011,32(23):2922-2932. .
[151]
MehtaSR, YusufS, PetersRJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study[J]. Lancet, 2001,358(9281):527-533.
[152]
WallentinL, BeckerRC, BudajA, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2009,361(11):1045-1057. .
[153]
LindholmD, VarenhorstC, CannonCP, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial[J]. Eur Heart J, 2014,35(31):2083-2093. .
[154]
MauriL, KereiakesDJ, YehRW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents[J]. N Engl J Med, 2014,371(23):2155-2166. .
[155]
BonacaMP, BhattDL, CohenM, et al. Long-term use of ticagrelor in patients with prior myocardial infarction[J].N Engl J Med, 2015, 372(19):1791-1800..
[156]
GiuglianoRP, WhiteJA, BodeC, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes[J]. N Engl J Med, 2009,360(21):2176-2190. .
[157]
StoneGW, McLaurinBT, CoxDA, et al. Bivalirudin for patients with acute coronary syndromes[J]. N Engl J Med, 2006,355(21):2203-2216. .
[158]
StegPG, JamesS, HarringtonRA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a platelet onhibition and patient outcomes (PLATO) trial subgroup analysis[J]. Circulation, 2010,122(21):2131-2141. .
[159]
MehtaSR, TanguayJF, EikelboomJW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial[J]. Lancet, 2010,376(9748):1233-1243. .
[160]
Bellemain-AppaixA, O′ConnorSA, SilvainJ, et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis[J]. JAMA, 2012,308(23):2507-2516. .
[161]
KoulS, SmithJG, SchersténF, et al. Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Eur Heart J, 2011,32(23):2989-2997. .
[162]
MontalescotG, van′t HofAW, LapostolleF, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction[J]. N Engl J Med, 2014,371(11):1016-1027. .
[163]
EllisSG, TenderaM, de BelderMA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction[J]. N Engl J Med, 2008,358(21):2205-2217. .
[164]
HerrmannHC, LuJ, BrodieBR, et al. Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals[J]. JACC Cardiovasc Interv, 2009,2(10):917-924. .
[165]
Van′tHAW, TenBJ, HeestermansT, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial[J]. Lancet, 2008,372(9638):537-546. .
[166]
StoneGW, WitzenbichlerB, GuagliumiG, et al. Heparin plus a glycoprotein Ⅱb/Ⅲa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial[J]. Lancet, 2011,377(9784):2193-2204. .
[167]
StoneGW, WitzenbichlerB, GuagliumiG, et al. Bivalirudin during primary PCI in acute myocardial infarction[J]. N Engl J Med, 2008,358(21):2218-2230. .
[168]
StegPG, van′t HofA, HammCW, et al. Bivalirudin started during emergency transport for primary PCI[J]. N Engl J Med, 2013,369(23):2207-2217. .
[169]
ShahzadA, KempI, MarsC, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial[J]. Lancet, 2014,384(9957):1849-1858. .
[170]
ValgimigliM, FrigoliE, LeonardiS, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes[J].N Engl J Med, 2015, 373(11):997-1009..
[171]
HanY, GuoJ, ZhengY, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial[J]. JAMA, 2015,313(13):1336-1346. .
[172]
BangaloreS, TokluB, KotwalA, et al. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors[J]. BMJ, 2014,349:g6419.
[173]
SchulzS, MehilliJ, NeumannFJ, et al. ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention[J]. Eur Heart J, 2010,31(20):2482-2491. .
[174]
LincoffAM, KleimanNS, KereiakesDJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein Ⅱb/Ⅲa blockade vs heparin and planned glycoprotein Ⅱb/Ⅲa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial[J]. JAMA, 2004,292(6):696-703. .
[175]
KastratiA, NeumannFJ, MehilliJ, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention[J]. N Engl J Med, 2008,359(7):688-696. .
[176]
NdrepepaG, SchulzS, KetaD, et al. Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality[J]. Am J Cardiol, 2010,105(2):163-167. .
[177]
MontalescotG, WhiteHD, GalloR, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention[J]. N Engl J Med, 2006,355(10):1006-1017. .
[178]
HammCW, BassandJP, AgewallS, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)[J].Eur Heart J, 2011, 32(23):2999-3054..
[179]
KastratiA, NeumannFJ, SchulzS, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction[J]. N Engl J Med, 2011,365(21):1980-1989. .
[180]
StegPG, JollySS, MehtaSR, et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial[J]. JAMA, 2010,304(12):1339-1349. .
[181]
MehtaSR, StegPG, GrangerCB, et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: arixtra study in percutaneous coronary intervention: a randomized evaluation (ASPIRE) pilot trial[J]. Circulation, 2005,111(11):1390-1397. .
[182]
BrenerSJ, MoliternoDJ, LincoffAM, et al. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention[J]. Circulation, 2004,110(8):994-998. .
[183]
SilvainJ, BeyguiF, BarthélémyO, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis[J]. BMJ, 2012,344:e553.
[184]
JamesS, AngiolilloDJ, CornelJH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the platelet inhibition and patient outcomes (PLATO) trial[J]. Eur Heart J, 2010,31(24):3006-3016. .
[185]
AndersonL, ThompsonDR, OldridgeN, et al. Exercise-based cardiac rehabilitation for coronary heart disease[J]. Cochrane Database Syst Rev, 2016,1:CD001800. .
[186]
van DijkMR, UtensEM, DulferK, et al. Depression and anxiety symptoms as predictors of mortality in PCI patients at 10 years of follow-up[J]. Eur J Prev Cardiol, 2016,23(5):552-558. .
[187]
中华医学会心血管病学分会,中国康复医学会心血管病专业委员会,中国老年学学会心脑血管病专业委员会. 冠心病康复与二级预防中国专家共识[J].中华心血管病杂志,2013,41(4):267-275. .
[188]
JangY, ZhuJ, GeJ, et al. Preloading with atorvastatin before percutaneous coronary intervention in statin-naïve Asian patients with non-ST elevation acute coronary syndromes: A randomized study[J]. J Cardiol, 2014,63(5):335-343. .
[189]
ZhengB, JiangJ, LiuH, et al. Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention: results of the ISCAP (intensive statin therapy for Chinese patients with coronary artery disease undergoing percutaneous coronary intervention) randomized controlled trial[J]. Euro Heart J, 2015, 17Suppl B:B47-B56..
[190]
CannonCP, BraunwaldE, McCabeCH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J]. N Engl J Med, 2004,350(15):1495-1504. .
[191]
ReinerZ, CatapanoAL, De BackerG, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)[J].Eur Heart J, 2011, 32(14):1769-1818..
[192]
LawMR, MorrisJK, WaldNJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies[J]. BMJ, 2009,338:b1665.
[193]
PfefferMA, BraunwaldE, MoyéLA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators[J]. N Engl J Med, 1992,327(10):669-677. .
[194]
GrangerCB, McMurrayJJ, YusufS, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial[J]. Lancet, 2003,362(9386):772-776. .
[195]
FlatherMD, ShibataMC, CoatsAJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)[J]. Eur Heart J, 2005,26(3):215-225. .
[196]
ZannadF, McMurrayJJ, KrumH, et al. Eplerenone in patients with systolic heart failure and mild symptoms[J]. N Engl J Med, 2011,364(1):11-21. .
[197]
SwedbergK, KomajdaM, BöhmM, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study[J]. Lancet, 2010,376(9744):875-885. .
[198]
de PeuterOR, LussanaF, PetersRJ, et al. A systematic review of selective and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure[J]. Neth J Med, 2009,67(9):284-294.